Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

oxygen

OXYGEN, USP

oxygen (OXYGEN, USP) is a essential for cellular homeostasis. Route of administration: inhalation. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 17
News articles 0
Drug details — oxygen
US status
approved
Class
—
Route
INHALATION
Patents
20
Programs
17
Data quality
0.84
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

oxygen (OXYGEN, USP) is a essential for cellular homeostasis. Route of administration: inhalation. Current US regulatory status: approved.

Key facts

INN oxygen
Brand OXYGEN, USP
Mechanism Essential for cellular homeostasis
Route INHALATION
Formulation GAS

Mechanism of action

Essential for cellular homeostasis

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline
  1. 2.16/VI/22 Phase 3 · Cardiol Therapeutics · Patients with functionally single ventricle (FSV - functiona
  2. DR240020 Phase 3 · Tour Hekla · Hypoxemic acute respiratory failure
  3. Oxygen (15-O) Water Phase 3 · BRIGHT MINDS BIOSCIENCES · Substance-Related Disorders
  4. APHP221166 Phase 2 · PARItec · gram-negative bacillus pneumonia acquired during mechanical
  5. Air médical en bouteille, OXYGEN Phase 2 · PARItec · Alternating Hemiplegia of Childhood
  6. Argon/Oxygen mixture, OXYGEN Phase 2 · Istituto Gentili Italia · Cardiac arrest
  7. Hyperbaric Oxygen Therapy Phase 2 · Summit Therapeutics · TBI Traumatic Brain Injury
  8. hyperbaric oxygen Phase 2 · United Therapeutics Europe · Breast Cancer

Related patents

Browse patents

  1. US 12311029

    Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12303618

    Oxygen-generating cryogels

    Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12233103

    Indoleamine 2,3-dioxygenase based immunotherapy

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12005194

    Configurable oxygen concentrator and related method

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11884707

    Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11878053

    Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11839659

    Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11648302

    Indoleamine 2,3-dioxygenase based immunotherapy

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11324813

    Indoleamine 2,3-dioxygenase based immunotherapy

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11274077

    4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11236044

    Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11173145

    Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11147801

    Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

    Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11078168

    Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11061094

    Simultaneous pH and oxygen weighted MRI contrast using multi-echo chemical exchange saturation transfer imaging (ME-CEST)

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11046649

    Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase

    Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10953187

    Configurable oxygen concentrator and related method

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10781183

    Small molecule inducers of reactive oxygen species and inhibitors of mitochondrial activity

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10752581

    4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10561763

    Oxygen generating biomaterial

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is oxygen?

oxygen (OXYGEN, USP) is a essential for cellular homeostasis. Route of administration: inhalation. Current US regulatory status: approved.

What is the brand name for oxygen?

OXYGEN, USP is a marketed brand name for oxygen. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of oxygen?

oxygen has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.